Trial Profile

Exploratory Study of NS-089/NCNP-02 in Duchenne Muscular Dystrophy

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brogidirsen (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions

Most Recent Events

09 Mar 2026 According to the NS Pharma media release, the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) presented 4.5-year safety and efficacy data based on the open-label extension study, including an investigator-initiated clinical trial of brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference from March 8-11, 2026.
10 Jan 2025 Results published in the Nippon Shinyaku Co., Ltd Media Release
28 Sep 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com